TXMD - TherapeuticsMD receives $15M equity investment from Rubric Capital

• TherapeuticsMD ( NASDAQ: TXMD ) received a $15M private investment in its common stock and a new series of preferred stock PIPE from Rubric Capital Management.
• Proceeds to be used for fulfilling its near-term operating capital requirements.
• In exchange for its initial $15M investment, Rubric received 565K shares of TherapeuticsMD common stock and 15K shares of newly designated Series A Preferred Stock, with a liquidation value of $1,333/share.
• Post transaction closure, Rubric will own ~18.3% of stock.
• The company also entered into an amendment with its lender, Sixth Street Specialty Lending, to extend the maturity date of of its financing agreement debt to Sep.30, 2022.
• The company also granted Sixth Street warrants to acquire 200K shares at an exercise price of $0.01 and would grant 125K additional common stock warrants for each additional monthly extension.
• It also has the option to further extend the maturity date until Oct. 31, 2022 and Nov. 30, 2022 if it receives additional equity capital of $7M per extension.

For further details see: